L-Carnitine (Levocarnitine)

8/10 · Labelled deficiency use; mixed human RCTs for other goals

Compound Profile

Overview

L-carnitine (levocarnitine) carries long-chain acyl groups into mitochondria for fatty-acid oxidation. Medicinal replacement addresses diagnosed carnitine deficiency; performance and fertility supplementation have separate, mixed evidence. [1–11]

The Energy & Endurance and Male Fertility author PDFs use a ready-to-use 500 mg/mL injectable formulation. Their phase schedules appear below, alongside a separate table of oral research interventions. [13,14]

Effects

• Labelled replacement for primary systemic and specified secondary carnitine deficiencies; a different indication from supplementation in replete adults. [1,2] [official product information]
• Wall 2011: muscle total carnitine +21% from baseline at 24 weeks with LC L-tartrate plus carbohydrate; n=14. [3] [human RCT]
• Wall 2011: work output +11% from own baseline and +35% versus carbohydrate control at week 24; not a universal performance or fat-loss estimate. [3] [human RCT]
• An earlier eight-man intervention found no significant improvement in muscle carnitine, maximal workload or maximal oxygen consumption. [10] [human intervention; negative]
• LC 2 g/day in a crossover study and LC 2 g/day + ALC 1 g/day for six months improved selected semen measurements in some analyses. [4,5] [human trials]
• The same LC/ALC daily amounts for 24 weeks produced no significant motility or total motile sperm-count benefit in 21 men. [7] [human RCT; negative]
• IV dialysis trials raised plasma carnitine but did not improve peak oxygen consumption in their primary analyses; fatigue-domain and secondary combined findings are distinct. [8] [human RCTs]
• TMAO experiments and human associations do not quantify supplementation-caused cardiovascular events; metabolic-syndrome RCT primary plaque volume was unchanged, with a concerning secondary stenosis signal. [9,11] [mixed experimental and human evidence]

Mechanism of Action

Carnitine supports the mitochondrial transport of long-chain acyl groups for fatty-acid oxidation. It also buffers acyl groups, helping preserve free coenzyme A, and forms acylcarnitines that facilitate disposal of accumulated acyl groups in particular metabolic disorders. These functions explain the rationale for replacing carnitine when availability is impaired. [1,2]

Supplementation depends on tissue uptake as well as intake. Plasma carnitine and muscle carnitine are different measurements: Wall measured muscle content directly, whereas dialysis studies measured circulating levels alongside functional outcomes. Intestinal microbes can also convert carnitine to trimethylamine, which is subsequently converted to TMAO. Koeth examined this pathway through mouse experiments, human dietary challenges and cardiovascular associations; the latter are observational rather than a randomised estimate of supplement-related cardiovascular events. [3,8,9]

Carnitine deficiency and metabolic disease

Official oral labelling covers primary systemic carnitine deficiency and secondary deficiency associated with specified inborn errors of metabolism. The cited injectable label includes prevention and treatment of deficiency in dialysis patients. Treatment is directed at a diagnosed deficiency and monitored clinically and biochemically. [1,2]

Exercise metabolism in healthy adults

Wall randomised 14 healthy men to carbohydrate control or L-carnitine L-tartrate plus carbohydrate for 168 days. Each of the two daily drinks contained 2 g tartrate (1.36 g active LC) and 80 g carbohydrate, giving 2.72 g active LC/day. At week 24, muscle total carnitine rose 21% from baseline; work output was 11% above the carnitine group’s own baseline and 35% above control. The study also found 55% less glycogen use at low-intensity exercise, greater PDC activation and lower muscle lactate at high intensity. [3]

An earlier longitudinal study in eight healthy men found no significant increase in muscle carnitine, maximal oxygen consumption, maximal workload or measured mitochondrial enzyme activity. The contrast points to formulation, carbohydrate co-intervention and tissue loading as important features of the positive trial, which was small and laboratory-based. [10]

Male infertility

Lenzi 2003 enrolled 100 men (86 completed) and used LC 2 g/day during two-month treatment periods within an eight-month crossover design. Lenzi 2004 enrolled 60 men (56 completed) and used LC 2 g/day plus ALC 1 g/day for six months. Both reported selected improvements in semen measurements; analyses and responses depended on patient selection and baseline values. Balercia’s multi-arm trial separately examined LC, ALC and their combination, with improvements in particular sperm kinetic measurements. [4–6]

Sigman 2006 enrolled 21 men (12 active, 9 placebo) and used LC 2 g/day plus ALC 1 g/day for 24 weeks, finding no clinically or statistically significant improvement in motility or total motile sperm counts. The combined evidence is mixed and centred on semen outcomes; live-birth benefit remains unestablished. [7]

Dialysis-related function and fatigue

Two placebo-controlled intravenous studies increased plasma carnitine and reported improvement in a fatigue domain. Peak oxygen consumption did not improve in either primary analysis; a secondary combined analysis suggested less deterioration in exercise capacity. These functional findings concern haemodialysis patients and are separate from the deficiency indication and healthy-person exercise studies. [8]

Cardiovascular and microbiome questions

Koeth linked microbial carnitine metabolism to TMAO production through animal experiments, human challenge work and observational cardiovascular data. A later RCT enrolled 157 participants with metabolic syndrome and carotid plaque: its primary plaque-volume endpoint showed no between-group difference, while a secondary analysis found greater stenosis progression with carnitine; total and LDL cholesterol also increased. This is a population-specific safety signal, not a demonstrated increase in heart attacks or strokes. The oral label separately cautions about TMA/TMAO accumulation in severe renal impairment. [1,9,11]

Oral research regimens

Wall: each drink contained 2 g tartrate = 1.36 g active LC plus 80 g carbohydrate in 700 mL; breakfast and four hours later. Lenzi 2003 used an eight-month crossover/washout design, not continuous eight-month LC. Sigman reported no significant semen benefit; the positive and negative findings remain distinct. [3–5,7]

Labelled deficiency dosing

Adult tablets: 990 mg two or three times daily (1.98–2.97 g/day). Oral solution: 1–3 g/day for a 50 kg adult, starting at 1 g/day and divided with meals. Dialysis injection: 10–20 mg/kg after a session, adjusted by monitoring. These indication-specific label regimens are distinct from the author protocol range. [1,2]

Biohacking & Off-Label Use

The Energy & Endurance author protocol uses injectable LC across an eight-week programme. Male Fertility uses it during weeks 9–12 of a sixteen-week programme; oral LC 2 g/day is listed in weeks 1–8 and 13–16. Both author PDFs use a ready-to-use 500 mg/mL formulation. [13,14]

Clinical exercise and infertility findings below come from specific oral interventions, often with carbohydrate or acetyl-L-carnitine. Those results do not validate the injectable author schedules. [3–7]

Routes of Administration

Ready-to-use injection — author protocols

The author PDFs specify a 500 mg/mL premixed formulation. Fertility’s general injection guide specifies subcutaneous administration; Energy’s LC entries say injectable without a separately confirmed SC/IM route. [13,14]

Oral — labels and research

Tablets, oral solution and LC L-tartrate were used for deficiency replacement or the oral interventions listed in Research Areas. [1,3–7,10]

IV — medicinal deficiency settings

The cited injection label describes metabolic/dialysis deficiency treatment, including 10–20 mg/kg after dialysis. This is separate from the author protocols. [2,8]

Dosing by Goal

• Energy & endurance: Energy PDF: weeks 1–6, 500 mg Mon/Wed/Fri; weeks 7–8, 250 mg Mon/Thu. Phase tables also say “or pre-workout”; master schedule specifies three weekly doses initially. [13]
• Male-fertility protocol: Fertility PDF: weeks 9–10, Mon/Wed/Fri; weeks 11–12, Mon/Thu, alongside HMG. Oral LC belongs to the other phases. These are author protocols, not injection efficacy trials. [14]

Dosing Protocol

Typical Range: 250–500 mg

Frequency: 2–3×/week

Cycle: 4–8 weeks

Loading Phase: No separate LC loading phase. Energy uses 500 mg three times weekly in weeks 1–6. [13]

Maintenance: Energy weeks 7–8: 250 mg Mon/Thu. Fertility injectable LC ends after week 12. [13,14]

Range and cycle summarise the two author protocols: Energy 8 weeks; Fertility injection phase 4 weeks. Neither is a universal clinical LC regimen. [13,14]

Stacking Guide

• Wall: daily amounts came from two drinks, each 2 g tartrate (= 1.36 g active LC) plus 80 g carbohydrate. Muscle LC +21%; work +11% versus own baseline and +35% versus carbohydrate control; n=14. This tests LC added to matched carbohydrate, not isolated LC, fat loss or removal of the carbohydrate partner. [3]
• Lenzi: 2003 found selected semen improvement after outlier exclusion; its LC-only crossover periods included washouts. In 2004, 60 enrolled/56 completed; selected motility improvements with LC+ALC did not isolate either ingredient’s contribution. [4,5]
• Sigman: n=21 (12 active/9 placebo), with no significant motility or total motile sperm-count benefit at the same combination doses. [7]
• Attribution: ALC is a distinct derivative. Balercia separately studied LC, ALC and their combination; selected kinetic endpoints do not establish live-birth benefit or efficacy of a complete injection protocol. No cited direct comparison establishes added benefit with GH peptides or multi-ingredient endurance programmes. [6]
• Interaction: increased INR with warfarin is a safety issue, not a beneficial stack. [1]

Administration Instructions

The two author PDFs describe premixed LC at 500 mg/mL, with no reconstitution: 500 mg = 1 mL, 250 mg = 0.5 mL. Energy’s supply table specifies two 5000 mg vials; Fertility specifies one. Their totals match 10,000 mg and 5,000 mg across the respective injection schedules. [13,14]

Fertility’s general guide specifies subcutaneous administration, site rotation and no mixing of compounds in one syringe. Energy’s LC-specific route is not separately confirmed by the cited entries. Follow the actual vial specification; “LC600 / 600 mg” without an explicit denominator does not establish mg/mL. [13,14]

Side Effects & Safety

• Nausea, vomiting, abdominal cramps, diarrhoea and body odour are reported in medicinal-product labels. [1,2]
• Seizures are reported with and without prior seizure history; existing seizures may become more frequent or severe. [1,2]
• IV hypersensitivity reports include anaphylaxis, laryngeal oedema and bronchospasm, mostly in dialysis patients. [2]
• Chronic high oral exposure in severe renal impairment may cause TMA/TMAO accumulation. [1]
• Warfarin interaction reports include increased INR; monitoring is important. [1,2]
• Pregnancy/lactation data are limited; label and postmarketing reports do not establish reliable event frequencies or safety of the author injection protocols. [1,2,13,14]

Contraindications

The cited labels list no known formal contraindications. Clinical cautions include hypersensitivity and seizure history, severe renal impairment and concomitant warfarin; INR monitoring is relevant with warfarin. Safety data in pregnancy and breastfeeding are limited. [1,2]

Legal Status by Region

FAQ

Is L-carnitine the same as levocarnitine?

Yes. Levocarnitine is the medicinal name for L-carnitine. L-carnitine L-tartrate is a salt formulation; acetyl-L-carnitine is a different derivative. [1–3]

Is the LC in the author protocols a powder?

No. Energy and Fertility describe a ready-to-use 500 mg/mL formulation, with no reconstitution. The Energy table names 5000 mg premixed vials. [13,14]

What dose, frequency and duration does Energy & Endurance use?

Weeks 1–6 use 500 mg three times weekly, Mon/Wed/Fri. Weeks 7–8 use 250 mg twice weekly, Mon/Thu. The eight-week total is 10,000 mg. At that PDF’s 500 mg/mL, these are 1 mL and 0.5 mL per administration. This is an author protocol, not a clinical injection-efficacy trial. [13]

How does the Male Fertility injection phase differ?

Injectable LC appears only in weeks 9–12: 500 mg Mon/Wed/Fri in weeks 9–10, then 500 mg Mon/Thu in weeks 11–12, following the HMG schedule. The phase total is 5000 mg. Oral LC 2000 mg/day belongs to weeks 1–8 and 13–16. The PDF specifies 500 mg/mL ready-to-use solution. [14]

Which doses and durations were studied for male infertility?

Lenzi 2003 used LC 2 g/day during two-month crossover treatment periods. Lenzi 2004 used LC 2 g/day plus ALC 1 g/day for six months. Sigman used the same daily combination for 24 weeks and found no significant benefit in motility or total motile sperm counts. These are daily totals; the cited abstracts do not specify every within-day split. [4,5,7]

How much active L-carnitine is in the tartrate dose?

In Wall’s preparation, 2 g L-carnitine L-tartrate supplied 1.36 g active L-carnitine. Twice daily gave 2.72 g active LC and 160 g carbohydrate per day. Salt mass and active-compound mass are different dose quantities. [3]

When is acetyl-L-carnitine included?

The Lenzi 2004 and Sigman 2006 fertility trials paired LC 2 g/day with ALC 1 g/day. ALC is a distinct ingredient, not another name for LC, so this is a two-compound combination, not 3 g of levocarnitine. Balercia also studied the ingredients separately. [5–7]

What monitoring or medical issues matter?

Official labels call for monitoring plasma carnitine, blood chemistries and clinical response in deficiency treatment. Warfarin users require INR monitoring; seizure history and hypersensitivity reactions matter. Severe renal impairment raises oral TMA/TMAO concerns, while IV dialysis-related deficiency treatment is a separate labelled setting. [1,2]

Research References

1. CARNITOR (levocarnitine) tablets — US prescribing information. DailyMed; official medicinal-product information, not a primary trial.
2. Levocarnitine injection — US prescribing information. DailyMed; official medicinal-product information, not a primary trial.
3. Chronic oral ingestion of L-carnitine and carbohydrate increases muscle carnitine content and alters muscle fuel metabolism during exercise in humans. 2011. Primary human RCT.
4. Use of carnitine therapy in selected cases of male factor infertility: a double-blind crossover trial. 2003. Primary human trial.
5. A placebo-controlled double-blind randomized trial of the use of combined l-carnitine and l-acetyl-carnitine treatment in men with asthenozoospermia. 2004. Primary human RCT.
6. Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. 2005. Primary human RCT.
7. Carnitine for the treatment of idiopathic asthenospermia: a randomized, double-blind, placebo-controlled trial. 2006. Primary human RCT; negative semen findings.
8. Intravenous L-carnitine increases plasma carnitine, reduces fatigue, and may preserve exercise capacity in hemodialysis patients. 2001. Primary report of two randomised trials.
9. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. 2013. Primary mixed experimental/observational study.
10. Long-term administration of L-carnitine to humans: effect on skeletal muscle carnitine content and physical performance. 2002. Small longitudinal human intervention; negative muscle-loading and maximal-performance findings.
11. Progression of atherosclerosis with carnitine supplementation: a randomized controlled trial in the metabolic syndrome. 2022. Primary human RCT; primary plaque-volume endpoint and secondary stenosis findings distinguished.
12. WADA 2026 Prohibited List. Official substance and method rules; M2.2.
13. Samir Levin. Energy & Endurance Protocol. Published author protocol; PDF pp. 8–11, 14. Ready-to-use LC 500 mg/mL and phase schedule; not an efficacy trial.
14. Samir Levin. Male Fertility Protocol. Published author protocol; PDF pp. 3, 9, 11, 13. Injectable LC phase and ready-to-use 500 mg/mL; not an efficacy trial.
15. PubChem CID 10917: levocarnitine. Chemical identity; CAS 541-15-1, C7H15NO3. Not a product formulation specification.

For educational and research purposes only. Not medical advice.